Efficacy of small‐molecule glycogen synthase kinase‐3 inhibitors in the postnatal rat model of tau hyperphosphorylation
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background and purpose: Glycogen synthase kinase‐3 (GSK‐3) affects neuropathological events associated with Alzheimeŕs disease (AD) such as hyperphosphorylation of the protein, tau. GSK‐3β expression, enzyme activity and tau phosphorylated at AD‐relevant epitopes are elevated in juvenile rodent brains. Here, we assess five GSK‐3β inhibitors and lithium in lowering phosphorylated tau (p‐tau) and GSK‐3β enzyme activity levels in 12‐day old postnatal rats. Experimental approach: Brain levels of inhibitors following treatment in vivo were optimized based on pharmacokinetic data. At optimal doses, p‐tau (Ser 396) levels in brain tissue was measured by immunoblotting and correlated with GSK‐3β enzyme activities in the same tissues. Effects of GSK inhibitors on p‐tau, GSK‐3β activities and cell death were measured in a human neuronal cell line (LUHMES). Key results: Lithium and CHIR98014 reduced tau phosphorylation (Ser 396) in the cortex and hippocampus of postnatal rats, while Alsterpaullone and SB216763 were effective only in hippocampus. AR‐A014418 and Indirubin‐3′‐monoxime were ineffective in either brain region. Inhibition of p‐tau in brain required several‐fold higher levels of GSK inhibitors than the IC 50 values obtained in recombinant or cell‐based GSK‐3β enzyme activity assays. The inhibitory effect on GSK‐3β activity ex vivo correlated with protection against cell death and decrease of p‐tau‐ in LUHMES cells, using low μ M inhibitor concentrations. Conclusions and Implications: Selective small‐molecule inhibitors of GSK‐3 reduce tau phosphorylation in vivo. These findings corroborate earlier suggestions that GSK‐3β may be an attractive target for disease‐modification in AD and related conditions where tau phosphorylation is believed to contribute to disease pathogenesis. British Journal of Pharmacology (2007) 152, 959–979; doi:10.1038/sj.bjp.0707471; published online 1 October 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244 · cited 3×
“…for example GSK-3b activity is normally inhibited by phosphorylation at Ser9 by kinases such as Akt and activated by auto-phosphorylation at Tyr216 (Cross et al., 1995; Lochhead et al., 2006), and that the basal activity of GSK-3b and distribution of kinases modulating GSK-3b phosphorylation (for…”
BackgroundInfluentialA protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 1×
“It is unlikely that lithium, being a reversible inhibitor of GSK-3b (Stambolic et al., 1996), remains bound to the enzyme after the immunoprecipitation procedure explaining the observed decrease in kinase activity.”
BackgroundTau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037 · cited 7×
“Recent studies have explored the involvement of GSK-3b in abnormal tau phosphorylation, NFT formation and APP processing (Pei et al., 1999; Ferrer et al., 2005).”
BackgroundInfluentialBramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., & Lee, V. M. Y. (1993) · Neuron · doi:10.1016/0896-6273(93)90057-x · Cited by 903 · cited 1×
“…several epitopes of p-tau such as AT8 and AT270 as with the Ser396 antibody, and phosphorylation of the latter epitope is clearly involved in PHF formation and microtubule destabilization (Bramblett et al., 1993), we decided to use the Ser396 antibody during the continuation of our study.”
MethodBancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818 · cited 6×
“GSK-3b phosphorylates sites corresponding to PHF-tau including Ser202, Ser396, Thr181 and Thr231 according to the longest human tau isoform containing 441 residues (Goedert et al., 1989; Hanger et al., 1998).”
BackgroundInfluentialNoble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 4×
“LiCl and AR-A014418, a thiazole class inhibitor, were shown to reduce insoluble, hyperphosphorylated tau in the brainstem of JNPL3 transgenic mice overexpressing a mutant form of human tau (Noble et al., 2005).”
BackgroundMethodInfluentialRamsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · cited 9×
“suppression of mutated tau overexpression led to improvements in memory function and neuroprotection despite the ongoing presence of NFT (Ramsden et al., 2005; SantaCruz et al., 2005).”
BackgroundInfluentialMitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer‐like state.
Drewes, G., Lichtenberg‐Kraag, B., Döring, F., Mandelkow, E. M., Biernat, J., Goris, J., Dorée, M., & Mandelkow, E. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05272.x · Cited by 565 · cited 1×
“Phosphorylation of tau by several kinases, including mitogen-activated protein kinase (MAPK), cyclin-dependent kinase 2/5 (CDK2/5), and glycogen synthase kinase-3b (GSK-3b) generates epitopes found in AD brains (Drewes et al., 1992; Baumann et al., 1993; Mandelkow et al., 1995).”
BackgroundRing, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Ma, S. T., Reeder, J. W., Samuels, I., Slabiak, T., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.3.588 · Cited by 532 · cited 4×
“developed for diabetes, showed efficacy in lowering the blood glucose levels in rodent disease models (Ring et al., 2003).”
BackgroundResultInfluentialPei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Gong, C.-X., Lidsky, T., Wegiel, J., Zuck, L., Grundke-Iqbal, I., & Iqbal, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5535 · Cited by 405
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain
PEI, J.-J., TANAKA, T., TUNG, Y.-C., BRAAK, E., IQBAL, K., & GRUNDKE-IQBAL, I. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199701000-00007 · Cited by 371
Tau domains, phosphorylation, and interactions with microtubules
Mandelkow, E.-M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., & Mandelkow, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00025-a · Cited by 308
PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7630 · Cited by 281
Tau Mutations Cause Frontotemporal Dementias
Goedert, M., Crowther, R. A., & Spillantini, M. G. (1998) · Neuron · doi:10.1016/s0896-6273(00)80615-7 · Cited by 268 · cited 4×
“known to arise from alternative splicing of exons 2, 3 and 10 and inclusion of N-terminal inserts (Goedert et al., 1998; Hong et al., 1998).”
BackgroundInfluentialGSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila
Mudher, A., Shepherd, D., Newman, T. A., Mildren, P., Jukes, J. P., Squire, A., Mears, A., Berg, S., MacKay, D., Asuni, A. A., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001483 · Cited by 265
Microtubule bundling by tau proteins in vivo: analysis of functional domains
Kanai, Y., Chen, J., & Hirokawa, N. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05489.x · Cited by 194
Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice
Ikeda, M., Kawarai, T., Kawarabayashi, T., Matsubara, E., Murakami, T., Sasaki, A., Tomidokoro, Y., Ikarashi, Y., Kuribara, H., Ishiguro, K., et al. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62274-2 · Cited by 120 · cited 1×
“Diverse transgenic mice models overexpressing mutant forms of tau have been developed in order to elucidate the mechanism behind tau pathology in neurodegenerative diseases such as FTDP-17 and AD (Spittaels et al., 1999; Ikeda et al., 2005; Boekhoorn et al., 2006).”
Background
Cited by
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Self-citationMao, Y., Ge, X., Frank, C. L., Madison, J. M., Koehler, A. N., Doud, M. K., Tassa, C., Berry, E. M., Soda, T., Singh, K. K., et al. (2009) · Cell · doi:10.1016/j.cell.2008.12.044 · Cited by 774
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
“More recently, numerous GSK3 inhibitors were investigated in 12-day-old rats that have increased tau phosphorylation compared with adult animal”
BackgroundGSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Eldar-Finkelman, H., & Martinez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 354
Metadata
- Authors
- Selenica, M., Jensen, H. S., Larsen, A. K., Pedersen, M. L., Helboe, L., Leist, M., & Lotharius, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 6
- Pages
- 959-979
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1999020480
- Cited by
- 131
- References
- 26
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.